Relationship between CSF tau biomarkers and structural brain MRI measures in frontotemporal lobar degeneration

J Neurol Sci. 2022 Nov 15:442:120415. doi: 10.1016/j.jns.2022.120415. Epub 2022 Sep 8.

Abstract

Background: Recently in the field neurodegenerative diseases increasing attention has been pointed to CSF biomarkers and their integration with neuroimaging (1). Frontotemporal lobar degeneration (FTLD) refers to a heterogeneous group of clinical syndromes with different underlying proteinopathies including tau pathology. CSF biomarkers have been proposed as diagnostic and prognostic factors. Aim of our study was to evaluate the relationship between CSF tau biomarkers and structural MRI brain measures in FTLD.

Methods: We included early FTLD patient. All included patients underwent lumbar puncture to evaluate amyloid, total-tau (t-tau), phospho-tau 181 (p-tau); p-tau/t-tau ratio was also calculated; brain MRI was performed to estimate whole brain volume, volume of principal deep grey matter structures and regional cortical thickness.

Results: Demographic characteristics of the 28 included patients were as follows: female/male: 9/19; mean ± SD age: 68.1 ± 7.8 years. The p-tau/t-tau ratio was significantly correlated with whole brain volume (r = 0.69; p: 0.001), left putamen volume (r = 0.55 p: 0.009), left pallidum volume (r = 0.41; p: 0.01), right accumbens area (r = 0.47; p: 0.02). P-tau/t tau ratio showed also a significant correlation with cortical thickness of left temporal lobe (r = 0.74; p: 0.001) and right lateral orbital frontal cortex (r = 0.45; p: 0.03). Linear regression showed a significant relationship between p-tau/t-tau ratio and left temporal pole (p = 0.01; r2: 0.60) and brain volume (p:0.002; r2: 0.56) after controlling for age and gender.

Conclusions: Our data suggest that CSF biomarkers, especially p-tau/t-tau ratio, could play a role as prognostic factor in FTLD. Further longitudinal investigations are needed to confirm these findings.

Keywords: Biomarkers; Brain volume; Cerebrospinal fluid; Frontotemporal lobar degeneration; MRI; Tau.

MeSH terms

  • Aged
  • Alzheimer Disease* / diagnosis
  • Amyloid beta-Peptides
  • Biomarkers
  • Brain / diagnostic imaging
  • Brain / pathology
  • Female
  • Frontotemporal Dementia* / pathology
  • Frontotemporal Lobar Degeneration* / diagnostic imaging
  • Humans
  • Magnetic Resonance Imaging
  • Male
  • Middle Aged
  • Neuroimaging
  • tau Proteins

Substances

  • tau Proteins
  • Biomarkers
  • Amyloid beta-Peptides